Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 163, Issue 3, 1999, Pages 1704-1710

  Perrin, Peter J ^a,d   June, Carl H ^b   Maldonado, Jairo H ^b   Ratts, Robert B ^c   Racke, Michael K ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d 909 BRB II ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; FEMALE; IMMUNOPATHOGENESIS; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD80; BINDING SITES, ANTIBODY; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033179230     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 258:1349.
2. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Rautlet, and J. P. Allison. 1992. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
3. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90:6586.
4. June, C. H., J. A. Ledbetter, P. S. Linsley, and C. B. Thompson. 1990. Role of the CD28 receptor in T-cell activation. Immunol. Today 11:211.
5. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
6. Thompson, C. B., T. Lindsten, J. A. Ledbetter, S. L. Kunkel, H. A. Young, S. G. Emerson, J. M. Leiden, and C. H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86:1333.
7. Saha, B., D. M. Harlan, K. P. Lee, C. H. June, and R. Abe. 1996. Protection against lethal toxic shock by targeted disruption of the CD28 gene. J. Exp. Med. 183:2675.
8. Lucas, P. J., I. Negishi, K. Nakayama, L. E. Fields, and D. Y. Loh. 1995. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154:5757.
9. Hutloff, A., A. M. Dittrich, K. C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopoulos, and R. A. Kroczek. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397:263.
10. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
11. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1032.
12. Walunas, T. L., C. Y. Bakker, and J. A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:2541.
13. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.
14. Perrin, P. J., J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1333.
15. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:783.
16. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, and G. Laszlo. 1993. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
17. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo Jr., L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
18. Caux, C., B. Vanbervliet, C. Massacrier, M. Azuma, K. Okumura, L. L. Lanier, and J. Banchereau. 1994. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180: 1841.
19. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
20. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 mono-clonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
21. Racke, M. K., D. E. Scott, L. Quigley, G. S. Gray, R. Abe, C. H. June, and P. J. Perrin. 1995. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96:2195.
22. Perrin, P. J., T. A. Davis, D. S. Smoot, R. Abe, C. H. June, and K. P. Lee. 1997. Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation. Immunology 90:534.
23. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
24. Perrin, P. J., D. Scott, T. A. Davis, G. S. Gray, M. J. Doggett, R. Abe, C. H. June, and M. K. Racke. 1996. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. J. Neuroimmunol. 65:31.
25. Perrin, P. J., D. Scott, L. Quigley, P. S. Albert, O. Feder, G. S. Gray, R. Abe, C. H. June, and M. K. Racke. 1995. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154: 1481.
26. Miller, S. D., C. L. Vanderlugt, D. J. Lenschow, J. G. Pope, N. J. Karandikar, M. C. Dal Canto, and J. A. Bluestone. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3:739.
27. Vanderlugt, C. L., N. J. Karandikar, D. J. Lenschow, M. C. Dal Canto, J. A. Bluestone, and S. D. Miller. 1997. Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. J. Neuroimmunol. 79:113.
28. Goverman, J., A. Woods, L. Larson, L. P. Weiner, L. Hood, and D. M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72:551.
29. Buenafe, A. C., R. C. Tsu, B. Bebo, A. A. Vandenbark, and H. Offner. 1997. Myelin basic protein-specific and TCR Vβ 8.2-specific T-cell lines from TCR Vβ 8.2 transgenic mice utilize the same Vα and Vβ genes: specificity associated with the Vα CDR3-J α region. J. Neurosci. Res. 47:489.
30. Deibler, G. E., R. E. Martenson, and M. W. Kies. 1972. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2:139.
31. Gross, J. A., E. Callas, and J. P. Allison. 1992. Identification and distribution of the costimulatory receptor CD28 in the mouse. J. Immunol. 149:380.
32. + splenic T cells after CD28 receptor ligation. J. Immunol. 154:985.
33. Pettinelli, C. B., R. B. Fritz, C. H. Chou, and D. E. McFarlin. 1982. Encephalitogenic activity of guinea pig myelin basic protein in the SJL mouse. J. Immunol. 129:1209.
34. Yoshimoto, T., and W. E. Paul. 1994. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179:1285.
35. Wu, Y., Y. Guo, A. Huang, P. Zheng, and Y. Liu. 1997. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J. Exp. Med. 185:1327.
36. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, and N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176:1595.
37. Blair, P. J., J. L. Riley, B. L. Levine, K. P. Lee, N. Craighead, T. Francomano, S. Perfetto, G. S. Gray, B. M. Carreno, and C. H. June. 1998. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukm-2 secretion but allows bcl-XL induction. J. Immunol. 160:12.
38. Wang, R., Q. Fang, L. Zhang, L. Radvany, A. Sharma, N. Noben-Trauth, G. B. Mills, and Y. Shi. 1997. CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J. Immunol. 158:2856.
39. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
40. Arima, T., A. Rehman, W. F. Hickey, and M. W. Flye. 1996. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J. Immunol. 156:4916.
41. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.
42. Cross, A. H., T. J. Girard, K. S. Giacoletto, R. J. Evans, R. M. Keeling, R. F. Lin, J. L. Trotter, and R. W. Karr. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:2783.
43. Hurwitz, A. A., T. J. Sullivan, M. F. Krummel, R. A. Sobel, and J. P. Allison. 1997. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 73:57.
44. Hohlfeld, R. 1996. Inhibitors of tumor necrosis factor-α: promising agents for the treatment of multiple sclerosis?. Mult. Scler. 1:376.
45. Korner, H., F. A. Lemckert, G. Chaudhri, S. Etteldorf, and J. D. Sedgwick. 1997. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T-cell infiltration to the central nervous system. Eur. J. Immunol. 27:1973.
46. Frei, K., H. P. Engster, M. Bopst, C. S. Constantinescu, E. Lavi, and A. Fontana. 1997. Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:2177.
47. Bachmaier, K., C. Pummerer, A. Shahinian, J. Ionescu, N. Neu, T. W. Mak, and J. M. Penninger. 1996. Induction of autoimmunity in the absence of CD28 co-stimulation. J. Immunol. 157:1752.
48. Lenschow, D. J., K. C. Herold, L. Rhee, B. Patel, A. Koons, H. Y. Qin, E. Fuchs, B. Singh, C. B. Thompson, and J. A. BLuestone. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285.
49. Vanderlugt, C. J., and S. D. Miller. 1996. Epitope spreading. Curr. Opin. Immunol. 8:831.
50. Krummel, M. F., T. J. Sullivan, and J. P. Allison. 1996. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int. Immunol. 8:519.
51. Perrin, P. J., E. Lavi, S. A. Zekavat, C. A. Rumbley, and S. M. Phillips. 1999. Experimental autoimmune meningitis: A novel neurological disease in CD28 deficient mice. Clin. Immunol. 91:41.
52. Jensen, M. A., B. G. Arnason, A. Toscas, and A. Noronha. 1996. Global inhibition of IL-2 and IFN-γ secreting T cells precedes recovery from acute monophasic experimental autoimmune encephalomyelitis. J. Autoimmun. 9:587.